Testing targeted drugs for meningioma that keeps growing
Original title: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so the drugs are still being tested in people.
The short version
This study is testing whether certain targeted drugs can slow a meningioma that is getting worse.
Who this trial is for. This trial is for people with a meningioma that is growing, spreading, or getting worse. It tests vismodegib, the FAK inhibitor GSK2256098, capivasertib, and abemaciclib.
Where it stands. This trial has not reported results. It is looking at how well these drugs work against a meningioma that is getting worse. The answer is not in yet.
What this means, and what it doesn't
What it could mean: These drugs are meant to block enzymes that tumor cells need in order to grow. Whether that actually helps people with meningioma is still an open question. Someone whose meningioma is getting worse could ask their care team whether a study like this is worth looking into.
What it doesn't mean: This does not mean these drugs are a proven treatment. A trial is a test, not care your own doctor can give you. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.